English Journal
- Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
- Magro M, Mas V, Chappell K, Vázquez M, Cano O, Luque D, Terrón MC, Melero JA, Palomo C.SourceBiología Viral, Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, 28220 Madrid, Spain.
- Proceedings of the National Academy of Sciences of the United States of America.Proc Natl Acad Sci U S A.2012 Feb 21;109(8):3089-94. Epub 2012 Feb 8.
- Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at ver
- PMID 22323598
- Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
- Groothuis JR, Hoopes JM, Hemming VG.SourceMedImmune, LLC, Gaithersburg, MD 20878, USA. GroothuisJ@MedImmune.com
- Advances in therapy.Adv Ther.2011 Feb;28(2):110-25. Epub 2011 Feb 4.
- Respiratory syncytial virus (RSV) causes significant morbidity in very young children, preterm infants with and without chronic lung disease, and children with hemodynamically significant congenital heart disease. In the absence of a safe and effective vaccine, alternative means of protecting high-r
- PMID 21318605
Related Links
- Easy to read patient leaflet for RespiGam. Includes indications, proper use, special instructions, precautions, and possible side effects. ... If OVERDOSE is suspected: Contact 1-800-222-1222 (the American Association of Poison ...
- Additional Information In the United States, more than 90,000 children are hospitalized and 4,500 die each year from the disease. Because RespiGam is made from human plasma, a small risk exists for the transmission of blood ...
Related Pictures
